ResearcherSichuan UniversityActive in the last 2 years

Rui Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-9020-4984; OpenAlex author ID A5115695180. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 26

Papers, trials and grants by year

2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 4

RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… Co-author DOI 10.21203/rs.3.rs-7291840/v1 ↗
Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal a… Co-author DOI 10.1038/s41392-024-02031-8 ↗
Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an o… Co-author DOI 10.21203/rs.3.rs-3677396/v1 ↗
Regional differences in islet amyloid deposition in the residual pancreas with new-onset diabetes secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.4240/wjgs.v15.i8.1703 ↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Junjie Xiong · 3 shared papers, 2023–2025 · strength 0.46
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Xiaoying Li · 2 shared papers, 2024–2025 · strength 0.32
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Yi Cheng · 2 shared papers, 2024–2025 · strength 0.32
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Chengjian Zhao · 2 shared papers, 2023–2025 · strength 0.31
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Zixing Huang · 2 shared papers, 2023–2025 · strength 0.31
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Ke Cheng · 2 shared papers, 2023–2025 · strength 0.31
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Wanrui Lv · 2 shared papers, 2023–2024 · strength 0.30
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗
Xu-Bao Liu · 1 shared paper, 2023 · strength 0.19
- Paper Regional differences in islet amyloid deposition in the residual pancreas with new-onset diabetes secondary to pancreat… DOI 10.4240/wjgs.v15.i8.1703 ↗
Chunlu Tan · 1 shared paper, 2023 · strength 0.19
- Paper Regional differences in islet amyloid deposition in the residual pancreas with new-onset diabetes secondary to pancreat… DOI 10.4240/wjgs.v15.i8.1703 ↗
Yonghua Chen · 1 shared paper, 2023 · strength 0.19
- Paper Regional differences in islet amyloid deposition in the residual pancreas with new-onset diabetes secondary to pancreat… DOI 10.4240/wjgs.v15.i8.1703 ↗
Chen Chang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Yi Zhang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Huanji Xu · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Bole Tian · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Dan Cao · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Xiaorui Zhu · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Qingqing Leng · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Wanting Hou · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Chenyan Zhang · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Bo Chen · 1 shared paper, 2025 · strength 0.16
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1 ↗
Heqi Yang · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Dan Cao · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Ke Cheng · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Bole Tian · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Dan Cao · 1 shared paper, 2023 · strength 0.14
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.